FDA Broadens Pitolisant Label - Takeaways - MDSpire

FDA Broadens Pitolisant Label

The US Food and Drug Administration approves pitolisant (WAKIX) tablets for the treatment of cataplexy in pediatric patients aged 6 years and older with narcolepsy.

  • By

  • Kathryn Wighton

  • February 17, 2026

  • 2 min

Share

  • 1

    Pitolisant is the only non-scheduled therapy approved in the US for narcolepsy in both pediatric and adult patients.

  • 2

    The FDA approved pitolisant for treating excessive daytime sleepiness and cataplexy in patients aged 6 years and older.

  • 3

    Pitolisant was initially approved in 2019 for excessive daytime sleepiness in adults and expanded to include cataplexy in 2020.

  • 4

    The drug acts as a selective histamine 3 receptor antagonist, promoting wakefulness through increased histamine release.

  • 5

    Common adverse reactions include insomnia, nausea, and anxiety in adults, while pediatric patients report headaches and insomnia.

Original Source(s)

FDA Broadens Pitolisant Label

  • by Kathryn Wighton

  • February 17, 2026

Related Content

Autism Announcement Changes Search Behavior

Online interest in leucovorin, folate products, and acetaminophen-related autism concerns increased markedly in the 2 weeks following the White House announcement.

How Does Social Media Influence Health Decisions?

National survey findings suggest many US adults report making health decisions based on social media despite widespread concerns about the accuracy of health information shared to the platforms.

Medical Oddities: Do Jellyfish Hold a Healing Secret?

Jellyfish, pets, watermelon, brain implants, and fennel fuel this week's surprises.